INDUCTION OF RAT PANCREATIC B-CELL TUMORS BY THE COMBINED ADMINISTRATION OF STREPTOZOTOCIN OR ALLOXAN AND POLY(ADENOSINE DIPHOSPHATE RIBOSE) SYNTHETASE INHIBITORS

  • 1 January 1985
    • journal article
    • research article
    • Vol. 45  (4) , 1845-1849
Abstract
Streptozotocin and alloxan were administered to Wistar rats in combination with poly(ADP ribose) synthetase inhibitors. Ten to 16 mo. after the injection of streptozotocin (50 mg/kg body wt i.v.) and 3-aminobenzamide (345 mg/kg i.v.) streptozotocin (50 mg/kg) and nicotinamide (350 mg/kg i.p.), streptozotocin (50 mg/kg) and picolinamide (250 mg/kg i.p.), alloxan (40 mg/kg i.v.) and nicotinamide (350 mg/kg), alloxan (40 mg/kg) and 3-aminobenzamide (345 mg/kg), and alloxan (40 mg/kg) and picolinamide (250 mg/kg), pancreatic islet cell tumors developed in 100, 98, 60, 26, 22 and 20% of surviving rats, respectively. After the single injection of streptozotocin and alloxan, islet cell tumors developed in 42 and 11% of surviving rats, respectively. The tumors were rich in B-granules on EM and contained as large amounts of proinsulin messenger RNA as normal pancreatic islets. Poly(ADP ribose) synthetase inhibitors enhance the tumorigenic effect of streptozotocin and alloxan on islet B-cells.